Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Journal of Clinical and Translational Hepatology,
Год журнала:
2024,
Номер
000(000), С. 000 - 000
Опубликована: Ноя. 4, 2024
With
the
rising
epidemic
of
obesity,
metabolic
syndrome,
and
type
2
diabetes
mellitus
in
China,
dysfunction-associated
non-alcoholic
fatty
liver
disease
has
become
most
prevalent
chronic
disease.
This
condition
frequently
occurs
Chinese
patients
with
alcoholic
hepatitis
B.
To
address
impending
public
health
crisis
its
underlying
issues,
Society
Hepatology
Medical
Association
convened
a
panel
clinical
experts
to
revise
update
"Guideline
prevention
treatment
(2018,
China)".
The
new
edition,
titled
for
(Version
2024)",
offers
comprehensive
recommendations
on
key
including
screening
monitoring,
diagnosis
evaluation,
treatment,
follow-up
steatotic
Metabolic
is
now
preferred
English
term
used
interchangeably
Additionally,
guideline
emphasizes
importance
multidisciplinary
collaboration
among
hepatologists
other
specialists
manage
cardiometabolic
disorders
effectively.
Язык: Английский
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Clinical and Molecular Hepatology,
Год журнала:
2024,
Номер
30(4), С. 989 - 991
Опубликована: Авг. 27, 2024
Язык: Английский